Crucell and NIH sign EUR 21.4 million Ebola Vaccine Manufacturing Contract
15-Apr-2005
Under the terms of the contract, Crucell will manufacture up to ten batches of clinical material of the PER.C6®-based Ebola vaccine in its own manufacturing facility. These materials will be used for Phase I and early Phase II clinical studies in humans. Crucell will receive up to EUR 21.4 million (US$ 27.6 million) from the VRC for the manufacturing of these clinical lots.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
How the sugar gets into the beet
Go to page
amp biosimilars AG - Hamburg, Germany
Go to page
Anadys Forms Collaboration With Gilead To Discover Novel Antiviral Compounds - Anadys’ uHTS-ATLAS™ to be used to screen important and challenging viral target
Go to page
ThromboGenics and BioInvent Publicate Data on a Novel Class of Angiogenesis Inhibitors - Novel anti-PlGF antibody, TB-403, being developed by ThromboGenics and BioInvent for
Go to page